e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Diagnosis and therapy of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
Kunihiko Yoshimura (Tokyo, Japan), Kunihiko Yoshimura, Miho Ejima
Source:
International Congress 2015 – Diagnosis and therapy of lung cancer
Session:
Diagnosis and therapy of lung cancer
Session type:
Thematic Poster Session
Number:
4293
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kunihiko Yoshimura (Tokyo, Japan), Kunihiko Yoshimura, Miho Ejima. Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung. Eur Respir J 2015; 46: Suppl. 59, 4293
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
RBM5 overexpression reverses acquired resistance to gefitinib in PC9/AB2 NSCLC cells
Source: International Congress 2016 – Late-breaking translational research in lung cancer
Year: 2016
Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015
Loss of heterozygosity of PTEN in patients with non-small cell lung cancer treated and not treated with neoadjuvant chemotherapy
Source: Annual Congress 2013 –Genetics and genomics of lung disease
Year: 2013
EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Effect of 17-oxo-DHA alone and in combination with gemcitabine on lung cancer cell growth
Source: International Congress 2016 – Late-breaking translational research in lung cancer
Year: 2016
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Abnormal abundance of senescent fibroblasts in the tumor stroma of non-small cell lung cancer patients
Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer
Year: 2013
Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Noninvasive detection of
EGFR
T790M mutation in gefitinib resistant non-small cell lung cancer using mutant-enriched PCR
Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Year: 2013
The influence of erythropoietin on growth and survival in non-small cell lung cancer cell lines
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Antitumor efficacy of the double suicide genesin lung cancer cells
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Epidermal growth factor receptor and related biomarkers evaluated by immunohistochemistry in patients with resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept